Drugs, Diagnostics and Delivery

From Personalised Medicine to Global Health

Wed 15 Sept 2010 from 5:30 -8 pm at the Birmingham Conservatoire

The face of healthcare is changing as our genomes are mapped and treatments become individually tailored.  

Although innovations and investment opportunities are now rapidly emerging, the life sciences industry is still realing from healthcare system reforms, increased regulations and patent expirations, and the time frame for successful commercialization remains long.

Join in the discussions and hear how the latest developments and discoveries in the the West Midlands could transform your healthcare system.

Science Capital and the Lunar Society are offering this interactive event to present some of our region's most exciting biomedical research discoveries, and to provide opportunities for businesses and investors to join in.

Experts from Advantage Business Angels, Beer & Partners, Blueberry, FD Solutions, HLBBshaw, MedilinkWM, Midven and the Mercia Technology Seed Fund will review business plans presented by three scientists.

Leading scientists at universities and NHS Trusts will reveal new ways to detect, prevent and treat cancer, lung and genetic diseases during this dinner event, which takes place during the British Science Festival.

Talks include:

Cancer Treatment, Diagnosis and Clinical Trials  

Professor Philip Johnson, Director of the Cancer Research UK Clinical Trials Unit, University of Birmingham, which runs up to forty trials at any one time, encompassing all stages of drug  development from ‘first use’ studies to  large randomized trials involving up to ten thousand patients.

The Brain Tumour Research Centre

Professor John Darling, Dean of the School of Applied Sciences and Director of the Research Institute in Healthcare Science, University of Wolverhampton, is focussing on the development and testing of novel therapeutics for malignant brain tumours.

Biomarkers: from research and development through to clinical studies

Dr Subhasis Banarjee, Director of Origin Biomarkers and based at Heartlands Hospital, won support from Advantage West Midlands to commercialise new  immunodiagnostic assays for pregnancy disorders, and is developing biological  markers for cancer and inflammatory disorders.

Meeting clinical needs through innovative technologies

Professor Monica Spiteri, Director of Lung Research at the University Hospital of North Staffordshire and Keele University, is developing near patient technologies for Chronic Obstructive Airways Disease with support from the National Institute of Health Research & NHS West Midlands Innovations.

Future Directions in Healthcare

Dr Alan Davies, Chief Medical Officer at GE Healthcare, presents on the convergence of biology, imaging and information technologies in healthcare, revealing how the treatment of cancer,  stroke and rheumatoid arthritis is being transformed.

People gather for the reception from 5:30pm and preview posters.  A set of engaging short talks begin at 6pm, followed by a lively panel discussion moderated by Tony Davis,CEO of MedilinkWM. Food and drinks will be served until 9pm, allowing plenty of time for networking and discussion.

Invited guests include prominent figures from business, academia, science and healthcare.

Supported by Anthony Collins Solicitors, Binding Site, Birmingham City Council, Birmingham Science City, Blueberry Consultants, FD Solutions, MedilinkWM, Netnak, Royal Society of Medicine and UnLtd.

The charity of the evening is Cure Leukaemia.

Sponsorships are a great way for companies and organizations to maximize the benefits, see details.